CONTINUATION PAGE: STAY WITHIN MARGINS INDICATED 
Principal Investigatof/Program Director (Last, first, middle): 
Wimperis JZ, Gottlieb D, Duncombe AS, Heslop HE, Prentice HG, Brenner MK. Requirements 
for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol 
144:541-547, 1990. 
Heslop HE, Bianchi ACM, Cordingley FT, Turner M, De Mel WCP, Hoffbrand AV, Brenner 
MK. Effects of a-interferon on autocrine growth factor loops in B lymphoproliferative 
disorders. J Exp Med 172:1729-1734, 1990. 
Bello-Fernandez C, Bird C, Heslop HE, Gottlieb DJ, Reittie JE, Rill DM, Holland M, Prentice 
HG, Brenner MK. Homeostatic action of Interleukin 4 on endogenous and rlL2 induced 
activated killer cell function. Blood 77:1283-1289, 1991. 
Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Hoffbrand 
AV, Brenner MK. Interleukin 2 infusion after autologous bone marrow transplantation 
accelerates hemopoietic regeneration. Transplant Proc 23:1704-1705, 1991. 
Oblakowski P, Bello-Fernandez C, Reittie JE, Heslop HE, Galatowicz S, Veys P, Wilkes S, 
Hazlehurst G, Hoffbrand AV, Brenner MK. Possible mechanism of selective killing of 
myeloid leukemic blast cells by lymphokine-activated killer cells. Blood 77:1 996-2001 , 
1991. 
Brenner MK, Heslop HE. Graft versus host reactions and bone marrow transplantation. Curr 
Opin Immunol 3:752-757, 1991. 
Katzav S, Cleveland JL, Heslop HE, Pulido D. Loss of the amino terminus helix loop helix 
domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol 
11:1912-1920, 1991. 
Brenner MK, Heslop HE. Immunotherapy of leukemia. Leukemia 6:76-79, 1992. 
Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Brenner MK. Interleukin 2 infusion 
abrogates humoral immunity. Clin Exp Immunol 87:493-498, 1992. 
Rencher SD, Hanif I, Heslop HE, Turner V, Brenner MK, Hurwitz JL. Reconstitution of the 
T-cell receptor a0 repertoire in recipients of allogeneic bone marrow transplant. Bone 
Marrow Transplant 10:521-527, 1992. 
Krance RA, Heslop HE, Mahmoud H, Ribeiro RC, Douglass EC, Hurwitz CA, Santana VM, 
Kun L, Horowitz MM, Brenner MK. Anti-pan T-lymphocytic ricin A chain immunotoxin 
(H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic 
BMT from HLA-DR identical sibling donors. Bone Marrow Transplant 1 1 :33-36, 1993. 
Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE. Correction of 
Duncan's syndrome (X-linked lymphoproliferative disorder) by allogeneic bone marrow 
transplantation. Lancet 342:587-588, 1993. 
Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Busche M, Krance RA, Anderson 
WF, Ihle JN. Gene marking to determine whether autologous marrow infusion restores 
long-term haempoiesis in cancer patient. Lancet 342:1134-1137, 1993. 
Heslop HE, Li C, Krance RA, Loftin SK, Rooney CM. Epstein-Barr infection after bone 
marrow transplantation. Blood 83:1706-1708, 1994. 
Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana VM, Ribeiro RC, 
Brenner MK, Heslop HE. Xomazyme CD5 immunotoxin in conjunction with partial T cell 
depletion as GVHD prophylaxis in pediatric patients receiving matched unrelated donor 
bone marrow transplantation. Bone Marrow Transplant (in press). 
Heslop HE, Brenner MK, Rooney CM, Krance RA, Roberts WM, Rochester R, Smith CA, 
Turner V, Sixbey J, Moen R, Boyett JM. Administration of neomycin resistance gene 
marked EBV specific cytotoxic T lymphocytes to recipients of mismatched related or 
phenotypically similar unrelated donor marrow grafts. Human Gene Ther 5:381-197, 
1994. 
Recombinant DNA Research, Volume 19 
[5111 
